Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Tropomyosin receptor kinase (TRK) fusions are detected in less than 2% of central nervous system tumors. There are limited data on the clinical course of affected patients.
Previous PostNRCAM Variant Defined By Microexon Skipping Is A Targetable Cell Surface Proteoform In High-Grade Gliomas
Next PostGermline Analysis Of An International Cohort Of Pediatric Diffuse Midline Glioma Patients
Apply to the CBTN Fellowship Program by completing the information below and uploading your one-page project proposal and current CV. Applications are reviewed on a rolling basis.
NOTE: The CBTN Fellowship Program is a research mentorship and engagement opportunity, not a grant or direct funding program.
